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Proteoforms in Acute Leukemia: 
Evaluation of Age- and Disease-
Specific Proteoform Patterns
Fieke W. Hoff, Anneke D. van Dijk and Steven M. Kornblau
Abstract
Acute leukemia are a heterogeneous group of malignant diseases of the bone 
marrow that occur at all ages. Acute lymphoid leukemia (ALL) accounts for about 
80% of all pediatric leukemia patients, whereas acute myeloid leukemia (AML) is 
more common in adults compared to pediatric patients. Despite similar patterns 
in the pathogenesis of acute leukemia in children and adults, clinical outcome in 
response to therapy differs substantially. Studying proteoforms in acute leukemia in 
children and adults, might identify similarities and differences in crucial signaling 
pathways that play a key role in the development or progression of the disease. In 
this chapter we will discuss how the study of proteoforms in acute leukemia could 
potentially contribute to a better understanding of the leukemogenesis, can help 
to identify effective targets for specific targeted treatment approaches in different 
subgroups of age and disease, and could aid the development of reliable biomarkers 
for prognostic stratification.
Keywords: acute myeloid leukemia, acute lymphoblastic leukemia, proteoforms, 
RPPA, pediatrics
1. Introduction
Acute leukemia forms a group of rapidly progressing malignant diseases char-
acterized by a block in the differentiation and an uncontrolled clonal proliferation 
of abnormal hematopoietic progenitor cells in the bone marrow and the peripheral 
blood [1, 2]. This accumulation of immature cells (“blasts”) interferes with the pro-
duction of normal blood cells, causing neutropenia, thrombocytopenia and anemia. 
According to the lineage of origin of the progenitor cells, the common lymphoid or 
the common myeloid, acute leukemia can roughly be classified into acute lympho-
blastic leukemia (ALL) and acute myeloid leukemia (AML).
Acute leukemia patients are diagnosed using morphologic, cytochemical and 
immunophenotypic methods, and are further sub-classified by chromosomal 
analysis and the presence or absence of somatically acquired gene mutations. While 
classification allows for prediction of outcome, the outcome risk of a large group 
of patients is still difficult to define. In addition, treatment options are expanding 
that treat patients based on their genetic abnormalities (in particular in the adult 
population), but so far most genetic abnormalities are not yet targetable, and most 
drugs that enter clinical trials rely on the increased abundance or altered activity of 
proteins, namely specific proteoforms, instead of the genetic lesion itself.
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Proteoforms are defined as different forms of a protein derived from a single 
gene, and include all forms of genetic variation (e.g. amino acid variation), alterna-
tive splicing, and post-translational modifications (PTM). This means that one 
transcribed gene can lead to a variety of protein structures, and that the biologi-
cal function of the final proteoform, as well as the cellular localization, binding 
partners and kinetics can vary greatly. As this suggests that gene sequences do not 
accurately predict the expression of a protein or whether the protein is stable or 
functional, it is not surprising that transcriptome data only correlates for about 
17–40% with protein abundance [3–5]. Proteoforms are the basic units of a pro-
teome. We believe that the study of proteoforms is an essential strategy to reveal 
cell dependencies and their underlying mechanism, and that this could add in the 
process of risk stratification and could identify novel therapeutic targets in highly 
complex diseases such as acute leukemia. Moreover, as the cure rates between ALL 
and AML, and between children and adults markedly differ, a direct comparison of 
the leukemic proteoforms between those patients, may aid to unravel the biological 
pathogenesis, and reveal similarities and dissimilarities that can propose therapeu-
tics that target these proteoforms in one disease, that could also be effective in an 
otherwise disparate leukemia that shares protein patterns.
2. Acute leukemia
2.1 Acute lymphoblastic leukemia
ALLs are neoplasms composed of immature B (pre-B), T (pre-T) or NK-cells 
that are referred as (“lymphoblasts”), of which the majority is pre-B ALL (85–90% 
in children vs. 75% in adults) [1]. It is the most common cancer in children and 
accounts for a quarter of all childhood malignancies. Although there are as many 
adults with ALL as there are children with the disease, the relative frequency in 
adults is much lower. Worldwide, the overall incidence is approximately 1–2 per 
100.000 people, with a peak incidence occurring in childhood and a second peak 
above the age of 50 years [6].
2.1.1 Cytogenetic abnormalities
Chromosomal aberrations are the hallmark of ALL and are often used to catego-
rize patients. In B-ALL, recurrent chromosomal abnormalities are found in 80% of 
the patients, including numerical and structural changes as translocations, deletions 
and inversions. There are substantial differences in the frequencies of occurring of 
cytogenetic abnormalities between children and adults [1, 7–10]. For instance, the 
translocation 9;22 [BCR-ABL1] is observed in 2–5% of the children compared to in 
30% of the adults, whereas the translation 12;21 [ETV6-RUNX1] is observed in 25% 
of the pediatric patients versus 3% in adult population. The hyperdiploid (gain of 
chromosomes) karyotype is present in 30–40% of the children compared to 3% in 
adults. Finally, translocation 4;11 resulting in the MLL-AF4 fusion gene, is detected 
in 60–80% of the infants (younger than 1 year old), whereas it is seen in only 2% of 
the patients up to 15 years and rare in adults. Hypodiploidy (loss of chromosomes) 
occurs in 5–6% of the ALL patients, independent of age.
Chromosomal translations occur less frequently in T-ALL compared to B-ALL 
(approximately 50–60%) and unlike in B-ALL their prognostic impact is not well 
defined and they are not used for risk stratification [10]. They are involved in both 
the T-cell receptor and the non-T-cell receptor loci on the chromosome or aberrant 
expression of the transcription factor oncogenes. There is less association with age [8].
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2.1.2 Prognosis
Survival in children with ALL is much better compared to adults, with the 
exception of infant ALL. In 60–80% of the cases, infant ALL is characterized by 
translocations involving 11q23, affecting the KMT2A gene. Aberrant KMT2A in 
ALL is associated with a high rate of early treatment failure and a very poor out-
come (long-term event-free survival of 28–45%), even when treated with more 
aggressive chemotherapy regimens [11, 12]. Historically, pediatric T-ALL was 
considered as high-risk disease. With the introduction of therapy intensification in 
T-cell ALL, this has changed to outcomes comparable to B-cell ALL, resulting in a 
five-year OS rate of more than 90% [13]. However, within certain high-risk sub-
groups (e.g. infants or children ≥10 years of age), 25–30% still experience relapse, 
which has a dismal outcome even with hematopoietic stem cell transplantation. 
Death resulting from treatment toxicity remains a challenge with an estimated 
10-year cumulative incidence of treatment-related death of 2.9% [14].
Survival for ALL in adults is around 45%, but patients above the age of 60 
suffer from inferior outcomes with only 10–15% long-term survival [10]. This is, at 
least partially, due to higher risk of medical comorbidities, the inability to tolerate 
standard chemotherapy regimens, and age-related unfavorable intrinsic biology 
such as Philadelphia chromosome positive, hypodiploidy and complex karyotype. 
However, as even the adolescents and young adults who lack medical comorbidities 
do significantly worse compared to their younger counterparts, the contribution of 
the different underlying biology should not be underestimated [8].
2.2 Acute myeloid leukemia
In general, patients with AML have similar signs and symptoms as patients with 
ALL which mainly includes symptoms related to (pan)cytopenia. AML is the most 
common acute leukemia in adults, whereas it is relatively rare in children (account-
ing for only 10% of the acute leukemia) [15]. Overall, AML occurs in 3–5 cases per 
100.000 people, and the incidence strongly increases with age.
2.2.1 Cytogenetic and molecular abnormalities
AML is a very heterogeneous disease and the identification of AML-associated 
chromosomal translocations and inversions have led to the current 2016 World 
Health Organization (WHO) classification system [16]. In this classification, 
eight recurrent genetic abnormalities (e.g. translocation (15;17) [PML-RARA], 
translocation (8;21) [RUNX1-RUNX1T1], inversion (16) or translocation (16;16) 
[CBFB-MYH1], translocation (9;11) [MLLT3-KMT2A], and translocation (9;22) 
[BCR-ABL1]) and their variants are included. In approximately 50 percent of 
patients, no cytogenetic abnormalities will be present, referred to as “normal 
karyotype” [17]. Additional classification in AML is provided by detection of one 
or more recurrent genetic mutations, with NPM1, FLT3, IDH1, IDH2, RUNX1 and 
CEBPA most studied.
Recently, the Therapeutically Applicable Research to Generate Effective 
Treatments (TARGET) study has presented the molecular landscape of nearly 1000 
pediatric AML patients that participated in several Children’s Oncology Group 
(COG) clinical trials [18]. Like adult AML, they found that pediatric AML has one 
of the lowest rates of mutations as compared to other cancers as recognized by The 
Cancer Genome Atlas, suggesting that the number of recognized recurrent muta-
tions in AML alone is not sufficient to explain its heterogeneity. They demonstrated 
that the landscape of somatic variants in pediatric AML was markedly different 
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from that reported in adults, highlighting the need for and facilitate the develop-
ment of age-tailored targeted therapies for the treatment of pediatric AML [19, 20].
2.2.2 Prognosis
Among adult patients who are under 60 years of age, AML can be cured in 
35–40% of the patients, whereas the survival rates of patients older than 60 is only 
5–15%. For older patients who are unable to receive intensive chemotherapy without 
acceptable side effects the prognosis is even more dismal, with a median survival 
of only 5–10 months [2]. Survival rates in the pediatric population, have improved 
greatly, although OS rates of 65–70% are still much lower than that for pediatric 
ALL [21].
3. Proteome differs from transcriptome
The human genome is the total amount of DNA that each cell in the body 
contains, including an estimated of 30,000–40,000 protein-coding genes. While 
the basic dogma of biology formerly was that DNA was transcribed into messenger 
RNA, which is then translated into proteins, and that mRNA levels could be used to 
predict protein abundance, it becomes more and more clear that this is overly sim-
plistic due to our expanding knowledge of the effects of epigenetics, environmental 
influences, mRNA editing, alternative splicing and noncoding RNAs on gene 
expression. For instance, coding single-nucleotide polymorphisms and mutations 
can affect the final protein sequence and function, and based on endogenous prote-
olysis and mRNA splicing, different isoforms can be generated from the same set of 
nucleotides. Additionally, after translation of the RNA transcript, proteins undergo 
multiple modifications affecting the protein function, localization, lifespan and 
activity. Together this results in up to a million of proteoforms.
One of the first studies back in 1999, that compared a limited number of mRNA 
and proteins using Saccharomyces cerevisiae, already concluded that the correlation 
between both was only 0.36 [4, 22]. And, even with the significant improvements in 
high-throughput genomic and proteome approaches, this fundamental observation 
continues to be widely, though not universally, supported, as most studies nowadays 
still show a correlation coefficient that varies between 0.17 and 0.40. Per example, 
Mun et al. recently performed correlation analysis of mRNA and protein log2-fold 
changes between gastric cancer tumor samples and adjacent normal tissues using 
6803 genes with protein and mRNA abundances available in at least 30% (≥24) 
of the patients. Of the 6803 genes, only 34.3% showed significant (FDR < 0.01) 
positive correlation with an average correlation coefficient of 0.28 [23]. Zang et al., 
performed an integrated proteogenomic analyses human colon and rectal cancer 
samples and while 89% of the samples showed significant positive mRNA-protein 
correlation (of which only 32% was significantly correlated), the average correla-
tion between messenger RNA transcript abundance and protein abundance was 
only 0.23 [24].
4. Age-associated proteoforms in acute leukemia
Aforementioned, the functional variant of a protein, the proteoform, is defined 
by genetics, mRNA editing, and PTMs. In particular in ALL, that peaks between 2 
and 5 years of age followed by a gradual increase in the older patients, is it suggested 
that different combinations of genetic factors (resulting in different proteoforms) 
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contribute to leukemogenesis at different ages. In order to answer the question why 
genes are differentially expressed upon age, a closer look at biological processes that 
influence the final proteoform production via pre-translational modifications may 
help. Here we will discuss a few examples of how these differ between younger and 
older patients with acute leukemia.
4.1 Genetic variants
Emerging genome wide sequencing techniques identified disease and age-spe-
cific gene variants in acute leukemia. For example, Perez-Andreu et al. discovered a 
single nucleotide polymorphism (SNP), a variant of the coding region of the DNA, 
of GATA3 on 10p14 that was associated with the susceptibility to ALL in adolescents 
and young adults, and that progressively increased with age [25]. Furthermore, 
genomic variants that occur in both pediatric and adult leukemia sometimes display 
a different phenotype at the protein level. As shown by Zuurbier et al., loss of PTEN 
protein due to the production of an unstable and truncated proteoform caused by 
a frameshift mutation or genomic deletion is a frequently seen in T-cell ALL (pre-
dominantly in pediatric T-ALL). PTEN is often recognized as a tumor suppressor, 
but its behavior and relation to outcome is highly context dependent. PTEN abnor-
malities may impact NOTCH1 and, in a cohort of PTEN mutated pediatric T-ALL 
patients (with loss of PTEN protein) that lacked the NOTCH1 activating mutations, 
had significantly fewer relapses compared to patients with activated PTEN and 
NOTCH1 [26]. In contrast, another study showed that PTEN mutations without 
NOTCH1 abnormalities were associated with poor prognosis in adults [37]. Thus, 
genomic mutations within the same gene, do not always produce the same proteo-
form with the same function. Mutations can create a proteoform with a completely 
different function and can convert a protein from a tumor suppressor into a tumor 
driver [27]. Although, genome wide studies are very meaningful in detection of 
conditions specific to age and disease, but the net effect on the cell largely depends 
on the production of the final proteoform (tumor suppressor or tumor driver) and 
the pathways they act in.
4.2 Chromosomal translocations
Chromosomal abnormalities, gene fusions and copy number aberrations are 
more common in the younger patient population [28]. The ratio of structural 
variation to mutational burden decreases continuously with age, with the most 
chromosomal translocations in infants (<1 year) compared to all other ages. Within 
this young age-group, the most common fusion involves KMT2A (also known 
as MLL1), present in 38% of the infants [28]. A second age-peak is recognized 
in young to middle aged AML adults. Overall, more than 80 fusion partners of 
KMT2A are described and it is the protein partner of KMT2A that determine 
characteristics specific to age and disease. Interestingly, 50% of the infants younger 
than 1 year with ALL contain the specific MLL-AF4 fusion protein caused by the 
t(4;11)(q21,q23) translocation [29], whereas in AML, the most common MLL 
rearrangement is the MLL-AF9 that arises from a t(9;11)(p22,q23) translocation. 
In both populations, MLL leukemia confers poor prognosis and identification of 
unique proteoforms in this subtype leukemia may guide treatment stratification by 
providing targetable leads. For instance, downstream proteomic targets mediated 
by MLL-AF4 include HOX, EPHA7, MEIS, PBX and GSK-3 and these are already 
considered or investigated as therapeutic targets in the context of MLL-rearranged 
leukemia. In addition, RAS, DOT1L, and HSP-90 also have been described as 
potential targets in MLL leukemia [30]. As those genes and their protein products 
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are in particular involved in transcription regulation, we hypothesize that patients 
that expression differences in those conserved genes, likely also harbor differences 
in abundance, or proteoforms of its downstream proteins, compared to wild-type 
patients.
4.3 Non-coding microRNAs
MicroRNAs (miRNA) are small non-coding RNAs that affect the proteome 
through their binding to mRNA influencing/inhibiting the translation to proteins. 
Aberrant miRNA expression is associated with leukemogenesis [31], and multiple 
miRNAs are found to be expressed differently upon age. A study by Noren Hooten 
et al. showed downregulation of miRNA expression in peripheral blood of healthy 
individuals with advancing age. Cancer is often age-related and five out of nine 
downregulated miRNAs in this study were related to cancer pathogenesis [32]. 
Another study compared miRNA profiles between pediatric and adult patients 
with AML and again, identified significant lower miRNA expression in adults 
compared to children. In addition, they found distinct miRNA expression pat-
terns in both t(8;21) and t(15;17) translocated pediatric AML, but not in adults. 
Also, nine-fold upregulation of miR-21 was identified in the MLL-rearranged 
pediatric patients compared to others and this finding was also not reflected by the 
MLL-rearranged adult population [33]. The identification of age-specific miRNA 
specific expressing in leukemia together with the fact that miRNA will affect the 
final proteomic state, indicates that further proteomic approaches could likely 
unravel differences in proteoforms between younger and older patients within 
leukemic subtypes.
4.4 Post-translational modifications
DNA is wrapped around histone to form a compact chromatin structure and 
PTMs on histone tails, such as the addition or removal of methyl or acetyl groups 
on lysine residues, or direct DNA methylation regulate chromatin accessibility 
and initiate and maintain gene expression patterns that account for specific cell 
lineage differentiation and development [34]. Packaging of the chromatin struc-
ture changes with age and include global loss of heterochromatin resulting in a 
more open chromatin state in the elderly. Reduction of heterochromatin due to 
increased histone acetylation during aging is also well-established [35, 36], but less 
well-characterized is the role of histone methylation. Since the prevalence of AML 
increases with age, we asked ourselves if histone methylation profiles are different 
between pediatric and adult AML. We recently applied RPPA-based profiling using 
antibodies against multiple histone methylation sites which enabled us to define 
disease and age characteristic patterns of histone modification. In agreement with 
our hypothesis, a significant decline in histone methylation was seen upon age in 
both ALL and AML cases (manuscript in preparation).
As mentioned, MLL-rearrangements are specific to age and disease, and are 
frequently altered in leukemia. As MLL fusion proteins modulate the chromatin 
structure by histone tail modifications, MLL-rearranged leukemia is considered as 
epigenetic malignancy. In addition, mutations in proteins that modify the histone 
PTM process (e.g. writers, erasers and readers) are more frequently found in T-ALL 
compared to other childhood malignancies, and distinct DNA methylation patterns 
were recognized among different subtypes of ALL. Those patterns correlated with 
changed transcriptomes. Aberrant DNA methylation is associated with silencing 
of genes that involved in lymphoid development, and contribute to leukemogen-
esis. By combining DNA methylation and transcriptome analysis, transcriptional 
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silencing via promotor hypermethylation was recently identified in pediatric AML 
[28], and correlated with age, karyotype and outcome.
Since hypomethylating agents have been widely used to treat, in particular the 
older leukemia patients, we hypothesize that proteomics can help to identify more 
refined subgroups (maybe even from the younger population) that can be treated 
with certain treatment regimens that alter the epigenome. For instance, the discov-
ery of a specific protein or proteomic signature (either related to the epigenome or 
not) that is correlated with sensitivity to hypomethylating agents, can potentially 
act as biomarker in MLL-rearranged leukemia, to select patients that can benefit 
from those agents. In the experimental setting, therapies with hypomethylating 
agents have already showed re-expression of the hypermethylated genes along 
with restored chemosensitivity, and in relapsed ALL, increased promotor methyla-
tion was found to be related to increased chemoresistance [37]. If it is possible to 
identify a set of proteins that is specific for relapsed MLL-rearrangement AML 
and/or ALL, rapid tests (e.g. ELISA, IHC or FPPA) could be developed to quickly 
provide information about the protein abundance in relapsed patients, to identify 
those who will benefit from additional treatment, as well as, a priori, predict which 
newly diagnosed patients are most likely to relapse, and treat those with additional 
treatment to prevent relapse.
5. Oncogenic proteoforms leading to leukemia
Mutations in the DNA of the hematopoietic stem cells play a pivotal role in 
leukemogenesis and within single genes, multiple mutations have been identified 
that results in different forms of the protein. One example involves transcription 
factor CCAAT/enhancer binding protein A (CEBPA) mutated AML patients, which 
is known to regulate growth arrest and differentiation in hematopoiesis by promot-
ing granulocyte lineage differentiation in common myeloid progenitor cells, and 
disruption of normal CEBPA expression in myeloid progenitors may lead to a block 
in granulopoiesis resulting in erythropoiesis in its place [38]. As critical regulator of 
myeloid lineage development it is not surprising that CEBPA is mutated in ~10% of 
AML patients and most frequently classified as myeloblastic AML subtype M1 of M2 
according the French-American-British (FAB) classification. CEBPA transcript trans-
lates for a full-length (CEBPA-p42) or shorter isoform (CEBPA-p30). CEBPA-p30 
isoforms contain the DNA binding domain but lack the N-terminal transactivation 
domain. However, CEBPA-p30 is dominant negative by reducing transcriptional 
activity after heterodimerization with full-length CEBPA-p42. About half of CEBPA 
mutated AML patients have one allele with a N-terminal mutation and one allele with 
a C-terminal mutation. The N-terminal mutant results in translational termination 
of the full-length isoform and increase truncated CEBPA-p30 expression. In contrast, 
C-terminal mutations in CEBPA-p42 are mostly characterized by in-frame basic 
region leucine zipper (bZIP) variants inhibiting normal CEBPA function by disrupt-
ing DNA binding and dimerization [39]. CEBPA mutated patients might be candi-
dates for inhibition of the oncogenic CEBPA-p30 isoform to recover the disrupted 
p42/p30-ratio.
6. High-throughput proteomics methodologies
Proteomics may be the least developed and investigated “-omics” approach, it is 
likely one of the most informative for understanding of cellular behavior as it can 
provide useful information about both protein abundance and activity, as regulated 
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by the PTM, the protein-protein and protein-DNA interactions. Nowadays, two 
of the most commonly used high-throughput techniques to study the proteome 
in leukemia are mass-spectrometry (MS)-based techniques and antibody-based 
techniques.
6.1 MS-based
MS is a high-throughput technique uses the formation of ions (charged frag-
ments) from the protein analyte to distinguish between proteoforms. Those ions 
can be sorted and measured using electrical and/or magnetic fields based on their 
mass-to-charge ratio (m/z), and identification of the protein follows based on the 
abundance of those m/z-fragments [40]. Globally, proteins can be ionized with two 
distinct methods: matrix assisted laser desorption/ionization (MALDI) and elec-
trospray ionization (ESI). In MALDI the protein sample is mixed with an energy 
absorbing matrix. Irradiation of this matrix causes vaporization of the matrix 
together with the sample, resulting in the formation of ions [41]. ESI creates ions 
using electrospray to dissolve the protein lysate, by applying high-voltage to the 
dissolvent to create an aerosol of small charged fragments. When a protein sample 
is highly complex, samples may require separation prior to MS analysis using 1D 
or 2D gel electrophoresis, high-pressure liquid chromatography (LC-MS), or gas 
chromatography (GC-MS) to maximize the sensitivity. Because proteoforms are 
derived from a single gene, they often contain homologous sequence regions, and 
because of the digestion step, information about the relationship between amino 
acid sequence and the PTM often lacks, this significantly complicates the process of 
identifying proteoforms. Several overviews have been published that discuss recent 
technological developments of MS to enable analysis distinct proteoforms [42–44].
6.2 Antibody-based
Another high-throughput approach is the protein microarray (PMA), of which 
two different types exist: forward phase protein arrays (FPPA) and reverse phase 
protein arrays (RPPA). Given that antibodies can be raised to specifically recognize 
sequence variations or PTM, they enable measurement of selected proteoforms. 
In FPPA, protein antibodies are immobilized on an array in known positions, and 
samples are then printed on the array. If a particular proteoform is present in the 
sample, the proteoform binds to the antibody and after exposure to a secondary 
antibody, the abundance can be measured. Each slide is incubated with a single 
protein sample, but multiple proteins can be measured simultaneously depending 
on the number of antibodies printed on the slide.
The “reverse” version of the FPPA is the RPPA methodology. In RPPA, samples 
are first printed on the array, and subsequently each slide is stained with a single 
protein antibody, followed by a secondary antibody to amplify the signal. The 
downsides of RPPA are that all samples must be printed at the same time to avoid 
methodological barriers due to printing irregularities between batches, and that 
RPPA can only be used to detect proteins for which a strictly validated antibody is 
available. As there is no separation of the proteins according to molecular weight, 
it is crucial that antibodies are proven to be highly specific, selective and reproduc-
ible. Plus, RPPA is biased to proteins and isoforms for which a strictly validated 
antibody is available. On the other hand, RPPA requires only a small number of 
cells (approximately 3 × 105 cells to test 400 different antibodies), making it highly 
suitable for retrospective clinical applications. As it in addition analyzes all samples 
at once, it allows a direct comparison of protein abundance across samples.
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7. Proteomics in acute leukemia
7.1  Disease-specific proteoform landscape of acute myeloid leukemia and acute 
lymphoid leukemia
Acute leukemia is a heterogeneous group of diseases both in terms of biology 
and prognosis. Classification into those arising from the myeloid or the lymphoid 
lineage is based on cytomorphology and cytochemistry, with further differentiation 
into specific subgroups based on morphology, immunophenotyping, cytogenetics, 
and molecular genetics of the acute leukemia cells. However, present classification 
systems are not adequate to differentiate between all subtypes and do not always 
accurately predict the clinical outcome. Whether changes in the leukemic cells that 
cause those differences are due to developmental, genetic, or environmental effects, 
they all are ultimately mediated by changes in protein abundance or modification. 
Therefore, we hypothesize that systematic comparative or differential proteomics 
can discover changes in the presence and quantity of individual proteoforms that 
underlie these cellular changes, and can add to current diagnostics, prognostics and 
therapeutics.
Assessment of the “diseased”-proteome compared to the proteome of the 
“normal/healthy” cells (e.g. CD34+, CD38+CD34+, CD38−CD34+; a discussion 
about the optimal normal comparator is discussed elsewhere [45]) can identify 
proteins that are aberrantly expressed or activated compared to normal, as well as 
can identify different forms of the same protein that differ between the diseased 
cell and the healthy comparator. This enables recognition of pathways utilization of 
cells present within a certain set of patients or related to a specific clinical feature. 
In addition, proteins or sets of proteins that are differentially expressed, may aid for 
confirmatory diagnostic purposes and early disease detection.
Furthermore, detailed proteomic profiling can help identifying differences 
between subgroups of diseases, including ALL and AML, and also between 
subgroups within one of both. It may be important (informative) to know how 
these two diseases are similar as well as how they differ. As ALL and AML are both 
dominated by immature malignant hematopoietic cells, they can serve as lineage-
independent control for each other. Defining which proteins display similar expres-
sion in ALL and AML, but which are different compared to the “normal” healthy 
control, or to more mature cells, are likely to be related to a block in differentiation, 
whereas other proteins patterns that are similar in both, could be related to the 
hallmark of uncontrolled proliferation, resistance to cell death, or other shared 
deregulations.
As example, Cui et al. performed proteomic analysis using 2D-MS for 61 bone 
marrow biopsies from patients diagnosed with French-American-British (FAB) 
M1-M5 AML or ALL [46, 47]. Comparative analysis, identified 27 proteins with 
lineage-specific expression. Among them, myeloperoxidase was already known to 
be highly expressed in AML compared to ALL, but they also recognized heat shock 
factor binding protein 1 (HSBP1) as being high in ALL. In addition, they found 
proteins that were higher expressed in M2 and M3 AML compared to M1, and 23 
proteins that were differentially expressed between granulocytic lineage (M1, M2, 
M3) AML, and AML derived from the monocytic lineage (M5). To prove clinical 
usefulness, Cui et al. also applied proteomic analysis to an AML-M3 bone marrow 
(which was classified based on morphology by the presence of atypical granules) 
from a patient who did not respond to the standard differentiation-inducing 
therapy with all-trans retinoic acid or As2O3. Their analysis showed that this sample 
exhibited a “protein expression profile” specific to M1, and not to M3, and after 
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changing this treatment to chemotherapy, the patient gained complete remis-
sion within 3 weeks. Xu et al. performed proteomic profiling of the bone marrow 
samples from patients with different subtypes of acute leukemia (APL, AML, ALL) 
and healthy volunteers by SELDI-TOF-MS. Based on 109 protein signatures, they 
constructed a proteomic-based classification model capable of replicating the mor-
phological and differentiation-based classification scheme of the well-established 
FAB system. Their results suggested that this mode could potentially serve as new 
diagnostic approach [48].
In our own group, we performed proteomic profiling using RPPA for 265 
patients, in which we were able to separate 3 clusters of proteins that tended to track 
similarly within a FAB class from a subset of 24 differentially abundant proteins 
and PTMs; myeloid subtypes (M0–M2), the monocytic subtypes (M4–M5), eryth-
roleukemia and megakaryocytic leukemia [49]. Foss et al. studied proteomics from 
4 AML patients and 5 ALL patients using LC-MS/MS in blasts, as well as in CD34+ 
cells from 6 healthy donors and mononuclear cells from 2 healthy donors to cor-
rect for mononuclear cell contamination. Blinded unsupervised clustering enabled 
grouping with each cell type forming a discrete cluster, suggesting that proteomics 
can indeed, at least in some cases, robustly distinguish known classes of leukemia.
Recently, another study by our group analyzed pediatric AML (n = 95) and 
pediatric ALL (n = 73) on RPPA for antibodies against 149 different total proteins in 
addition to 45 antibodies recognizing different PTMs (e.g. phosphorylation, histone 
modification and cleavage) [50]. We felt that traditional hierarchical clustering was 
suboptimal as it weighs all proteins equally, in all situations across the dataset, and 
is agnostic to all known functional relationships between proteins, ignoring known 
interactions. Hence, we developed a novel computational method that accounts for 
known functional interactions which we call the “MetaGalaxy” approach [50–52]. 
This methodology starts with the allocation of proteins into groups of proteins with 
a related function based on existing knowledge or strong association within this 
dataset (“Protein Functional Group” (PFG), n = 31). For each PFG, a clustering 
algorithm enabled recognition of an optimal number of protein clusters; a subset of 
cases with similar (correlated) expression of core PFG components.
In order to know how the activity between the different PFG relate to each other 
within pediatric ALL and AML, we next hypothesized that there would be recurrent 
patterns of interaction between the various PFG clusters that would form a finite set 
of “protein expression signatures” that are shared by different subsets of patients. 
Therefore, patients were clustered based on their protein cluster membership using 
a binary matrix system. Correlation between protein clusters from various PFG was 
defined as a “Protein Constellation”. We were able to identify subgroups of patients 
(signatures) that expressed similar combinations of protein constellations.
With this segmented approach a substantial amount of structure was observed 
across the data set (Figure 1), with an optimal number of 12 constellations and 
12 signatures. Notably, signatures were strongly associated the leukemia-lineage. 
Signature 1 and 2 were specific to T-ALL (Figure 1, annotated in pink), whereas 
signatures 3, 4 and 5 were dominant to B-ALL and signature 7–12 to AML. Only 
signature 6 was a mixture of both B-ALL and AML patients. This clear distinction 
could also be discerned by the constellations. Protein constellation 1–4 were all 
specific to ALL, with constellation 1 (Figure 1, magenta box) only being found in 
B-ALL, 4 exclusively to T-ALL (Figure 1, yellow box), and 2 and 3 being present in 
both B- and T-ALL. On the other hand, constellation 7 and 8 were strongly associ-
ated with AML (Figure 1, blue box) and constellation 5 and 6 were found in both 
ALL and AML.
We also identified proteins that were universally changed in the same direction 
in at least 6 of the 8 signatures. Interestingly, GATA1 and STAT1 were universally 
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lower expressed in both pediatric AML and adult AML patients, whereas and 
phosphorylated RB1-pSer807_811, a phosphorylation event that deactivates the RB1 
protein, showed universally opposite expression in children and adults, being 
predominantly unphosphorylated (active) in pediatric patients and highly phos-
phorylated (inactive) in adults. For pediatric AML and ALL samples, comparable 
expressions were seen for the higher expressed universals CASP7 cleaved at domain 
198 and phosphorylated CDKN1B-pSer10, and the lower expressed JUN-pSer73 and 
GATA1.
Unpublished data from 205 adult AML and 166 adult ALL patients identified 
the existence of 11 protein signatures, of which 5 were AML dominant (93–100%), 
4 were T-ALL dominant (79–100%) and 2 signatures contained a mixture of AML, 
B-ALL, T-ALL samples (50 and 68% AML). Three out of the 12 constellations were 
predominantly associated with AML, 4 were associated with ALL, 2 were associated 
with a mixture of ALL and AML cases, and 3 signatures were not strongly associ-
ated with any particular signature. This study used a total of 230 antibodies, includ-
ing antibodies against 169 different proteins along with 52 antibodies targeting.
phosphorylation sites, 6 targeting Caspase and Parp cleavage forms and 3 
targeting histone methylation sites. A third study (manuscript in preparation) 
from 500 pediatric AML, 68 adult T-ALL and 290 pediatric T-ALL patients, again 
showed similar results, with T-ALL and AML dominant signatures (81.5–100%), 
and only 1 out of the 15 signatures that had both T-ALL and AML (39% T-ALL and 
61% AML). This clearly suggests that proteomics can be used to distinguish ALL 
from AML, and that although ALL and AML are very different in terms of overall 
proteomics, they share “protein expression signatures”, which suggests that there 
Figure 1. 
“MetaGalaxy” analysis for pediatric ALL and AML. Annotations shows clear separation in protein patterns 
for T-ALL (magenta; signature 1 and 2), B-ALL (yellow; signature 3, 4, and 5), and AML (blue; signature 
7, 8, 9, 10, 11, and 12). Constellations 1 (horizontally, magenta box) is associated with T-ALL, constellation 
4 (horizontally, yellow box) with B-ALL and constellation 7 and 8 with AML (horizontally, blue box). This 
figure was adapted from Hoff et al. Molecular Cancer Research 2018 [50].
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are shared patterns of deregulation within some pathways. However, as all studies 
used a mixture of both total and PTM-proteins, it would be interesting to assess 
how expression and classification differs across diseases using a panel with a larger 
number of PTM, or a panel limited to PTM only, given that PTM often provide 
information about the activity or biological function of the protein.
7.2 Global proteomic landscape of pediatric and adult T-ALL
When we assessed the global proteomic landscape in pediatric and adult T-ALL, 
using the “MetaGalaxy” approach, we found 10 signatures based on 11 constella-
tions (manuscript in preparation). Overall, signatures were not associated with age 
(i.e. pediatric vs. adult), with the exception of one signature. This signature was 
strongly associated with 2 constellations, which were only present in this particular 
signature. This suggests that pediatric T-ALL and adult T-ALL are more similar than 
ALL and AML, but that despite mostly overlapping signatures and constellations, 
there is an expression pattern specific to children. As this is similar to what we see in 
the genetics, were most recurrent aberrations are seen in both children and adults, 
but with different frequencies of occurring, correlation with genetic features would 
be interesting.
7.3 Assessing dynamic change upon treatment exposure
Children have a significant better prognosis and ALL responds better to treat-
ment than AML. In addition to extracting information about differences in baseline 
protein abundance between those groups of patients, another consideration is to 
look at the dynamic response of the cells to stress, such as chemotherapy, or apop-
totic inducers, to see whether changes in protein abundance patterns can provide 
a marker or whether a cell is responsive or resistant, and whether this is different 
between patients. Looking at post-treatment abundance and presence of proteo-
forms may provide insights into biological effects of drugs and mechanisms of drug 
resistance. This can either be done from static expression levels post-treatment at 
a given time point, or from the dynamic change in expression during treatment 
(i.e. expression post-treatment minus expression pre-treatment). Particularly, in 
leukemia, were blood can easily be drawn from the patient without performing any 
additional invasive procedures, expression can be measured at several time points 
during treatment.
Although this will not provide a priori information about which patients 
will respond to therapy or which patient needs which chemotherapy, it can give 
information about the response to treatment during early stages and so, aid in the 
decision of a more intensive treatment strategy should be achieved, or whether 
additional combinational treatment would be beneficial. For instance, if it is known 
that a particular protein pathway is utilized be the cell in order to circumvent cell 
death, in theory, this pathway can be targeted. Also, by comparing response to 
treatment on protein abundance or activity between ALL and AML, or children and 
adults, this can provide important information about why some patients respond 
while others do not.
While, theoretically, this approach would be promising, in reality this it much 
more complicated. First, of all, the time point of measuring the expression would be 
crucial. Assessment of the dynamic change too early, in cells that are not yet fatally 
hit by the chemotherapy or are in the process of dying, would suggest that the che-
motherapy does not work, or has no effect on protein level, whereas measuring too 
late would measure the expression in cells that already died. Moreover, despite the 
ability of chemotherapy to kill the vast majority of leukemic cells, the rare leukemic 
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stem cell that survives the chemotherapy, and that is responsible for the outgrowth 
of the leukemia cells which is manifested as relapse or primary resistant disease, 
is the cell from which we can potentially gather the most information. Proteomic 
analysis of these resistant cells, rather than taking the average of all, might be more 
informative than the analysis of the bulk leukemia population. Especially, knowing 
how those cells respond to chemotherapy (in comparison to other), would then be 
likely to raise new biological questions about why different cells behave differently, 
and why, or how, cells are able to circumvent chemotherapy, and what can be done 
to treat those cells. However, without a current means to a priori identify those few 
cells, isolation of (enough of) those cells remain a real challenge. So, if we want to 
know what is going in, pre- and post-treatment, as means to identify who those are, 
is required.
8. Conclusions
Despite significant improvement in treatment regimes, outcomes of both pediat-
ric and adult patients with acute leukemia remain unsatisfactory. When a leukemia 
patient enters the clinic, particularly cytogenetics and mutation analysis are the 
methods of choice to perform risk stratification. And after induction therapy, 
choice of consolidation therapy is mainly based on the present chromosomal 
alternations and driver mutation(s). Emerging research in the field shows that 
prognosis is largely context-dependent and that acute leukemia are molecularly 
diverse diseases with similar phenotypes. Many years of exploration the molecular 
diversity in leukemia taught us that the combined influences of genetics, epigenetic 
remodeling, the microenvironment and PTM of leukemic blasts determine its cell 
fate. Since the net effect of these combined influences is predominantly displaced 
on the abundance and activity of the proteoforms, as well or their affected signaling 
pathways, we argue that characterization of differentially abundant proteoforms 
and recognition of proteomic patterns within and between (subgroups of) acute 
leukemia may facilitate and improve risk stratification as well as could provide 
therapeutic leads that may contribute to treatment personalization. However, while 
much is known about cytogenetics in AML and ALL, little is known about the 
proteomics of these cells.
While distinct proteoform patterns within and between different leukemic sub-
types are only beginning to be recognized, age-specific proteome characterizations 
are far more limited. Bone marrow aspiration is a relative painful procedure and 
healthy donors, such as patient relatives or medical students who donate bone mar-
row that could function as internal control against AML blasts are scarce in many 
studies. The control group therefore often does not represent the median age of 
the patient cohort and leukemic-specific findings cannot be directly compared to a 
matched age group. Many studies focusing on leukemia therefore avoid controls and 
perform internal disease comparisons. Age-related analysis is then only applicable 
when a wide age distribution across the cohort is present, but this is often not the 
case as most research focuses on either pediatric or adult leukemia, instead of both.
More research is needed to identify single proteins and sets of proteins that 
are associated with disease and age specific subgroups. As far as we know, we are 
the first to analyze protein abundance and their PTM between AML and ALL 
across all ages, using antibody-based proteomics. Almost all studies look at AML 
or ALL and if they look at both, they mainly focus on the differences rather than 
the similarities. However, ALL and AML share the same pathophysiology in terms 
of the occurrence of a differentiation block that gives rise to uncontrolled clonal 
proliferations of immature hematopoietic progenitor cells in the bone marrow. 
Proteoforms
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Defining which proteoforms have similar expression in ALL and AML, but differ-
ent expression compared to the “normal” healthy control or to more mature cells 
are likely to be related to a block in differentiation. Other similar protein patterns 
could be related to the hallmark of an uncontrolled proliferation or resistance to 
apoptosis. Identification of differences in proteomic profiles between ALL and 
AML can additionally lead to lineage-specific proteomic signatures which may help 
to distinguish (subgroups) of the diseases.
Recognition of similar and dissimilar proteomic patterns among acute leukemia 
should also be analyzed in relation to responses to therapy. Treatment that is used 
in one group that was highly sensitive to it can be tested in other groups based on 
similar proteomic patterns. Cytogenetic and mutational information provides prog-
nostic information, but so far lacks the a priori information to predict treatment 
outcomes. Rational selection of targeted therapies based on the functional activity 
state of the cell, as determined by the proteome, is more likely to sensitize patients 
for certain treatment regimens compared to random selection.
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